Cite
Bardia A, Su F, Solovieff N, et al. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precis Oncol. 2021;5doi: 10.1200/PO.20.00445.
Bardia, A., Su, F., Solovieff, N., Im, S. A., Sohn, J., Lee, K. S., Campos-Gomez, S., Jung, K. H., Colleoni, M., Vázquez, R. V., Franke, F., Hurvitz, S., Harbeck, N., Chow, L., Taran, T., Rodriguez Lorenc, K., Babbar, N., Tripathy, D., & Lu, Y. S. (2021). Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO precision oncology, 5. https://doi.org/10.1200/PO.20.00445
Bardia, Aditya, et al. "Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib." JCO precision oncology vol. 5 (2021). doi: https://doi.org/10.1200/PO.20.00445
Bardia A, Su F, Solovieff N, Im SA, Sohn J, Lee KS, Campos-Gomez S, Jung KH, Colleoni M, Vázquez RV, Franke F, Hurvitz S, Harbeck N, Chow L, Taran T, Rodriguez Lorenc K, Babbar N, Tripathy D, Lu YS. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precis Oncol. 2021 Sep 01;5. doi: 10.1200/PO.20.00445. eCollection 2021. PMID: 34504990; PMCID: PMC8423397.
Copy
Download .nbib